Opportunities for Our Referring Physicians
Dana-Farber Cancer Institute is a principal teaching affiliate of Harvard Medical School. Through continuing medical education (CME) and continuing educational unit (CEU) courses, we share advances in cancer research and treatment with the health care
community. We also provide educational programs for nurse practitioners, nurses, physician assistants, administrators, and others involved in cancer care and research.
Clinical courses are offered in conjunction with Harvard Medical School, which is accredited by the Accreditation Council for Continuing Medical Education (ACCME). Harvard Medical School designates these educational activities as credit towards the AMA
Physician's Recognition Award. Other courses are offered directly by Dana-Farber or by Partners HealthCare.
HSCT/HM Grand Rounds
The HSCT program's CME-accredited weekly Grand Round lectures cover a broad range of timely and clinically important topics related to bone marrow transplantation. These are available to physicians, mid-level practitioners, and nurses. Speakers are drawn
from Dana-Farber, Brigham and Women's Hospital, Harvard Medical School, and other regional and national institutions. The Grand Rounds are also webcast to ensure that anyone interested is able to view the presentations.
To attend or learn more about Grand Rounds, email bmtgrandrounds@dfci.harvard.edu.
Observerships
As a leading provider of cancer care and research, we attract researchers and clinicians who seek opportunities to learn from us. We offer observerships for physicians, mid-level practitioners, and nurses to shadow clinicians in the Hematologic Malignancies
department. While observerships are overseen organizationally by Dana-Farber, curricula and scheduling are managed directly by each department.
For HM and stem cell transplant observerships, please email HMobserverships@dfci.harvard.edu.
Stem Cell Transplantation and Cellular Therapies Annual Symposium: The Changing COVID-19 Landscape
This year's program will examine the impact of COVID-19 on stem cell transplant and cellular therapies, as well as important topics related to short- and long-term survivorship.
View the agenda and register online today.
Subscribe to "Advances in Hematologic Malignancies," a free biannual eNewsletter providing updates about Dana-Farber Brigham Cancer Center’s
hematologic oncology research and care, current clinical trials, and upcoming CME programs.